Septerna, Inc. (SEPN) stock
Close on Nov 11, 2026Market cap $2.27BP/E –Yield –
Septerna, Inc. grew revenue 336.7% to $96.27M over the twelve months to Sep 30, 2026. Free cash flow was -$77.59M, down 175.2% from a year earlier. At the latest close the market valued the company at $2.27B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.27B
- P/E ratio
- –
- Price to sales
- 23.55
- Price to book
- 5.30
- Dividend yield
- –
- Free cash flow yield
- -3.42%
Fundamentals
- Revenue
- $96.27M
- Net income
- -$59.00M
- EPS, diluted
- -$1.29
- Free cash flow
- -$77.59M
- Book value per share
- $9.12
- Diluted shares
- 47M
Trading
- Next earnings
- Mar 8, 2027 (estimated, after the close)
- Previous close
- $52.34
- Open
- $51.90
- Day's range
- $45.26 – $53.34
- Volume
- 1,127,480
- Average volume (20 days)
- 405,131
- Index membership
- Russell 2000 (since Dec 2024), Russell 3000 (since Feb 2025)
- Beta (5 years)
- 1.94
- 52-week range
- $18.19 – $53.34
- RSI (14 days)
- 63.1
- Volatility (1 year)
- 68.0%
- Relative volume
- 2.81×
- WACC
- 14.6%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SEPN | S&P 500 | Difference | SEPN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +26.6% | -2.4% | +29.0 pts | ||
| 3 months | +1.7% | -1.2% | +2.8 pts | ||
| Year to date | +74.2% | +12.3% | +61.9 pts | ||
| 1 year | +152.4% | +12.4% | +139.9 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Septerna filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Results
About Septerna
Pharmaceutical Preparations
Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops oral small molecule drugs targeting G protein-coupled receptors. The company utilizes a proprietary platform to isolate, purify, and reconstitute receptor proteins outside cells to guide structure-based drug design and optimization. Its development pipeline includes experimental product candidates such as SEP-479 and SEP-631, which focus on endocrinology, immunology, inflammation, and metabolic conditions. Septerna also partners with pharmaceutical companies, including Novo Nordisk, to develop oral therapies for disorders such as obesity and type 2 diabetes. Its programs aim to serve patient populations affected by these diseases.
Company profile, executives and historySepterna stock: common questions
What is Septerna's stock price?
SEPN closed at $48.56 on Nov 11, 2026, down 7.22% on the day. Over the past 52 weeks it traded between $18.19 and $53.34.
What is Septerna's market cap?
Septerna was worth $2.27B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SEPN's P/E ratio?
Septerna lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.29), so it has no meaningful P/E ratio.
How much revenue does Septerna make?
Septerna reported revenue of $96.27M for the twelve months to Sep 30, 2026, up 336.7% from a year earlier.
Does Septerna pay a dividend?
No. Septerna has not paid a cash dividend over the last twelve months.
When does Septerna report earnings next?
Septerna is expected to report Q4 FY2026 results on Mar 8, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SEPN stock performed over the past year?
Including dividends, SEPN returned +152.4% over the past year, against +12.4% for the S&P 500.
How many SEPN shares are sold short?
3M shares were sold short at the latest FINRA report, 9.99% of the float, or 11.9 days of average trading volume.
Who are Septerna's competitors?
Companies most similar to Septerna by business, industry and size include ENTA, WVE, VTVT, AMLX, FULC.
See a number that looks wrong?